SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 13, 2002
OraSure Technologies, Inc.
--------------------------
(Exact name of issuer as specified in charter)
DELAWARE 1-10492 36-4370966
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation or file Identification
Organization) number) Number)
150 Webster Street
Bethlehem, Pennsylvania 18015
(Address of principal executive offices)
(610) 882-1820
(Registrant's telephone number, including area code)
Item 5 - Other Events.
OraSure Technologies, Inc. (the "Company") issued a press release on May 13,
2002, announcing receipt of notification from the U.S. Food and Drug
Administration that the OraQuick(R) Rapid HIV-1 Antibody Test is approvable,
subject to the Company meeting certain conditions. A copy of the press release
is attached to this Report as Exhibit 99 and is incorporated herein by
reference.
Item 7. - Financial Statements and Exhibits.
(c) Exhibits.
Exhibits are listed on the attached exhibit index following the signature
page of this Report.
Signatures
Pursuant to the requirements of the Securities and Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized.
OraSure Technologies, Inc.
Date: May 13, 2002 By: /s/ Jack E. Jerrett
-----------------------------------
Jack E. Jerrett
Vice President, General Counsel
and Secretary
EXHIBIT INDEX
Exhibit
-------
99 Press Release issued May 13, 2002 by the Company announcing receipt of
notification from the U.S. Food and Drug Administration that the
OraQuick(R) Rapid HIV-1 Antibody Test is approvable, subject to the
Company meeting certain conditions.